Статья
Транссептальное эндоваскулярное протезирование митрального клапана
В обзоре представлены данные о современном направлении в транскатетерном лечении структурной патологии сердца — транссептальном эндоваскулярном протезировании митрального клапана (ТЭМК), которое становится альтернативным методом лечения у больных митральным пороком сердца. Несмотря на то, что трансапикальный транскатетерный доступ технически более простой, транссептальный подход менее инвазивный, подтверждает свою эффективность и прогнозируется как наиболее перспективный. В обзоре описаны актуальность, показания, методология подбора необходимого эндопротеза, этапы вмешательства, осложнения, порядок послеоперационного наблюдения пациентов после ТЭМК. Анализируются результаты публикаций, представляющих ТЭМК. Приводится клинический пример ТЭМК.
1. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a populationbased study. Lancet. 2006;368(9540):1005-11. doi:10/1016/S0140-6736(06)69208-8.
2. Coffey S, Cairns BJ, Iung B. The modern epidemiology of heart valve disease. Heart. 2016;102:75-85. doi:10.1136/heartjnl-2014-307020.
3. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739-91. doi:10.1093/eurheartj/ehx391.
4. Шарифулин Р. М., Богачев-Прокофьев А. В., Журавлева И. Ю. и др. Результаты транскатетерного протезирования митрального клапана. Российский кардиологический журнал. 2018;23(11):137-44. doi:10.15829/1560-4071-2018-11-137-144.
5. Paradis JM, Del Trigo M, Puri R, Rodés-Cabau J. Transcatheter Valve-in-Valve and Valvein-Ring for Treating Aortic and Mitral Surgical Prosthetic Dysfunction. J Am Coll Cardiol. 2015;66(18):2019-37. doi:10.1016/j.jacc.2015.09.015.
6. Vohra HA, Whistance RN, Roubelakis A, et al. Outcome after redo-mitral valve replacement in adult patients: a 10-year single-centre experience. Interact Cardiovasc Thorac Surg. 2012;14:575-9. doi:10.1093/icvts/ivs005.
7. Bourguignon T, Bouquiaux-Stablo AL, Loardi C, et al. Very late outcomes for mitral valve replacement with the Carpentier-Edwards pericardial bioprosthesis: 25-year follow-up of 450 implantations. J Thorac Cardiovasc Surg. 2014;148:2004-11.e1. doi:10.1016/j.jtcvs.2014.02.050.
8. Papadopoulos N, Dietrich M, Christodoulou T, et al. Midterm survival after decalcification of the mitral annulus. Ann Thorac Surg. 2009;87:1143-7. doi:10.1016/j.athoracsur.2008.12.041.
9. Eleid MF, Cabalka AK, Williams MR, et al. Percutaneous Transvenous Transseptal Tra nscatheter Valve Implantation in Failed Bioprosthetic Mitral Valves, Ring Annuloplasty, and Severe Mitral Annular Calcification. JACC Cardiovasc Interv. 2016;9(11):1161-74. doi:10.1016/j.jcin.2016.02.041.
10. Eleid MF, Whisenant BK, Cabalka AK, et al. Early Outcomes of Percutaneous Transvenous Transseptal Transcatheter Valve Implantation in Failed Bioprosthetic Mitral Valves, Ring Annuloplasty, and Severe Mitral Annular Calcification. JACC Cardiovasc Interv. 2017;10(19):1932-42. doi:10.1016/j.jcin.2017.08.014.
11. Yoon SH, Whisenant BK, Bleiziffer S, et al. Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification. Eur Heart J. 2019;40(5):441-51. doi:10.1093/eurheartj/ehy590.
12. Overtchouk P, Piazza N, Granada J, et al. Advances in transcatheter mitral and tricuspid therapies. BMC Cardiovasc Disord. 2020;20(1):1. doi:10.1186/s12872-019-01312-3.
13. Webb JG, Murdoch DJ, Boone RH, et al. Percutaneous Transcatheter Mitral Valve Repla cement: First-in-Human Experience With a New Transseptal System. J Am Coll Cardiol. 2019;73(11):1239-46. doi:10.1016/j.jacc.2018.12.065.
14. Modine T, Vahl TP, Khalique OK, et al. First-in-Human Implant of the Cephea Transseptal Mitral Valve Replacement System. Circ Cardiovasc Interv. 2019;12(9):e008003. doi:10.1161/CIRCINTERVENTIONS.119.008003.
15. Søndergaard L, De Backer O, Franzen OW, et al. First-in-Human Case of Transfemoral CardiAQ Mitral Valve Implantation. Circ Cardiovasc Interv. 2015;8(7):e002135. doi:10.1161/CIRCINTERVENTIONS.115.002135.
16. Cullen MW, Cabalka AK, Alli OO, et al. Transvenous, antegrade Melody valve-in-valve implantation for bioprosthetic mitral and tricuspid valve dysfunction: a case series in children and adults. J Am Coll Cardiol Intv. 2013;6:598-605.
17. Fassa AA, Himbert D, Brochet E, et al. Transseptal transcatheter mitral valve implantation for severely calcified mitral stenosis. JACC Cardiovasc Interv 2014;7:696-7. doi:10.1016/j.jcin.2013.12.204.
18. Søndergaard L, Brooks M, Ihlemann N, et al. Transcatheter mitral valve implantation via transapical approach: an early experience. Eur J Cardiothorac Surg. 2015;48(6):873-8. doi:10.1093/ejcts/ezu546
19. Ussia GP, Quadri A, Cammalleri V, et al. Percutaneous transfemoral-transseptal implantation of a second-generation CardiAQ mitral valve bioprosthesis: first procedure description and 30-day follow-up. EuroIntervention. 2016;11:1126-31. doi:10.4244/EIJY15M09_01.
20. Taramasso M, Gavazzoni M, Nickenig G, Maisano F. Transcatheter mitral repair and re placement: which procedure for which patient? EuroIntervention. 2019;15(10):867-74. doi:10.4244/EIJ-D-19-00743.
21. De Bonis M, Ferrara D, Taramasso M, et al. Mitral replacement or repair for functional mitral regurgitation in dilated and ischemic cardiomyopathy: is it really the same? Ann Thorac Surg. 2012;94:44-51. doi:10.1016/j.athoracsur.2012.01.047.
22. Dayan V, Soca G, Cura L, Mestres CA. Similar survival after mitral valve replacement or repair for ischemic mitral regurgitation: a meta-analysis. Ann Thorac Surg. 2014;97:758-65. doi:10.1016/j.athoracsur.2013.10.044.
23. Goldstein D, Moskowitz AJ, Gelijns AC, et al. Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. N Engl J Med. 2016;374:344-53. doi:10.1056/NEJMoa1512913.
24. Obadia JF, Messika-Zeitoun D, Leurent G, et al. MITRA-FR Investigators. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. 2018;379:2297-306. doi:10.1056/NEJMoa1805374.
25. Stone GW, Lindenfeld J, Abraham WT, et al.; COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379:2307-18. doi:10.1056/NEJMoa1806640
26. Baldetti L, Melillo F, Beneduce A, et al. Transcatheter Mitral Valve Implantation: Who are we Treating and What may we Expect? Am J Cardiol. 2019;123:1884-5. doi:10.1016/j.amjcard.2019.02.048.
27. Theriault-Lauzier P, Mylotte D, Dorfmeister M, et al. Quantitative multi-slice computed tomography assessment of the mitral valvular complex for transcatheter mitral valve interventions part 1: systematic measurement methodology and inter-observer variability. EuroIntervention. 2015;11:e1011-20. doi:10.4244/EIJY15M11_09.
28. Bapat V. Valve-in-valve apps: why and how they were developed and how to use them. EuroIntervention. 2014;10 Suppl U:U44-51. doi:10.4244/EIJV10SUA7.
29. Bapat V, Attia R, Thomas M. Effect of valve design on the stent internal diameter of a bioprosthetic valve: a concept of true internal diameter and its implications for the valve-invalve procedure. J Am Coll Cardiol Intv. 2014;7:115-27. doi:10.1016/j.jcin.2013.10.012.
30. Urena M, Himbert D, Brochet E, et al. Transseptal Transcatheter Mitral Valve Replacement Using Balloon-Expandable Transcatheter Heart Valves A Step-by-Step Approach. J Am Coll Cardiol Intv. 2017;10:1905-19. doi:10.1016/j.jcin.2017.06.069.
31. Blanke P, Dvir D, Cheung A, et al. Mitral annular evaluation with CT in the context of transcatheter mitral valve replacement. J Am Coll Cardiol Img. 2015;8:612-5. doi:10.1016/j.jcmg.2014.07.028.
32. Bapat V, Pirone F, Kapetanakis S, et al. Factors influencing left ventricular outflow tract obstruction following a mitral valve- in-valve or valve-in-ring procedure, part 1. Catheter Cardiovasc Interv. 2015;86:747-60. doi:10.1002/ccd.25928.
33. Blanke P, Naoum C, Dvir D, et al. Predicting LVOT obstruction in transcatheter mitral valve implantation: concept of the neo-LVOT. J Am Coll Cardiol Img. 2017;10:482-5. doi:10.1016/j.jcmg.2016.01.005.
34. Wang DD, Eng M, Greenbaum A, et al. Predicting LVOT obstruction after TMVR. J Am Coll Cardiol Img. 2016;9:1349-52. doi:10.1016/j.jcmg.2016.01.017.
35. Ren B, Rahhab Z, von der Thusen J, et al. Transcatheter Lotus valve implantation in a stenotic mitral valve. J Am Coll Cardiol Intv. 2016;9:e215-7.
36. Vahanian A, Himbert D, Brochet E. Transseptal puncture. In: Di Mario C, Dangas GD, Barlis P, editors. Interventional Cardiology: Principles and Practice. London: Wiley-Blackwell 2011:383-93. doi:10.1002/9781118983652.ch62.
37. Maisano F, La Canna G, Latib A, et al. Transseptal access for MitraClip procedures using surgical diathermy under echocardiographic guidance. EuroIntervention. 2012;8:579-86. doi:10.4244/EIJV8I5A89.
38. Fassa AA, Himbert D, Vahanian A. Mechanisms and management of TAVR-related complications. Nat Rev Cardiol. 2013;10:685-95. doi:10.1038/nrcardio.2013.156.
39. Fassa AA, Himbert D, Brochet E, et al. Emergency transseptal transcatheter mitral valveinvalve implantation. EuroIntervention. 2013;9:636-42. doi:10.4244/EIJV9I5A101.
40. Guerrero M, Wang DD, O’Neill W. Percutaneous rescue of an embolized valve after transcatheter mitral valve replacement. J Am Coll Cardiol Intv. 2017;10:627-9. doi:10.1016/j.jcin.2017.01.020.
41. Naksuk N, Asirvatham SJ. Iatrogenic atrial septal defect: reassurance or inquisitiveness. J Interv Card Electrophysiol. 2018;52(2):137-40. doi:10.1007/s10840-018-0369-4.
42. Stone GW, Vahanian AS, Adams DH, et al. Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: a consensus document from the Mitral Valve Academic Research Consortium. J Am Coll Cardiol. 2015;66:278-307. doi:10.1016/j.jacc.2015.05.046.
43. Wang DD, Guerrero M, Eng MH, et al. Alcohol Septal Ablation to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Replacement. J Am Coll Cardiol Intv. 2019;12:1268-79. doi:10.1016/j.jcin.2019.02.034.
44. Khan JM, Bch BM, Babaliaros VC, et al. Anterior Leaflet Laceration to Prevent Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Replacement. J Am Coll Cardiol. 2019;73:2521-34. doi:10.1016/j.jacc.2019.02.076.
45. Guerrero M, Wang DD, Himbert D, et al. Short-term results of alcohol septal ablation as a bail-out strategy to treat severe left ventricular outflow tract obstruction after transcatheter mitral valve replacement in patients with severe mitral annular calcification. Catheter Cardiovasc Interv. Off J Soc Card Angiogr Interv. 2017;90(7):1220-6. doi:10.1002/ccd.26975.
46. Taramasso M, Nietlispach F, Schmid M, Maisano F. Corevalve Evolut R implantation to treat severe left ventricle outflow tract obstruction following mitral valve-in-ring: first-inman report. Eur Heart J. 2016;37:317. doi:10.1093/eurheartj/ehv617.
47. Nguyen A, Urena M, Himbert D, et al. Late displacement after transcatheter mitral valve replacement for degenerative mitral valve disease with massive annular calcification. J Am Coll Cardiol Intv. 2016;9:1633-4. doi:10.1016/j.jcin.2016.05.033.
48. Bapat VV, Khaliel F, Ihleberg L. Delayed migration of Sapien valve following a transcatheter mitral valve-in-valve implantation. Catheter Cardiovasc Interv. 2014;83:E150-4. doi:10.1002/ccd.25076.
49. Capretti G, Urena M, Himbert D, et al. Valve thrombosis after transcatheter mitral valve replacement. J Am Coll Cardiol. 2016;68:1814-5. doi:10.1016/j.jacc.2016.07.757.